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Summary.-A new, stable platinum coordination complex (FLAP) containing the
5-nitroimidazole, metronidazole, has been prepared and characterized. The square-
planar platinum(II) complex has two metronidazole molecules and two chlorine
atoms in the cis configuration. The properties of FLAP differ significantly from
metronidazole alone or other platinum complexes tested in the same system. It has a
low toxicity towards Chinese hamster ovary cells and is a very effective
radiosensitizer toward hypoxic cells in vitro: a one-h pretreatment with a non-toxic
dose of 50 ytM gave an enhancement ratio of2-4. No potentiation of aerated cells to X-
irradiation damage was observed after a similar schedule of pretreatment at the
higher dose of 100 /uM FLAP.
THE ACHIEVEMENT oflocal control in the
radiotherapy of tumours is often limited
by regions of radioresistant but viable
hypoxic cells. Hence there has been great
interest in chemotherapeutic agents which
can sensitize hypoxic tumour cells to
ionizing radiation. Our aim was to design a
new radiosensitizer, incorporating features
of existing agents in a single compound. A
combination of platinum and metroni-
dazole, a nitroimidazole was chosen.
Cis-dichloro-diammine platinum(II)
(Neoplatin) (Fig. la) is a potent anti-
tumour agent now used in the clinic, but
which also acts as a radiosensitizer both in
mammalian and bacterial systems (Rich-
mond et al., 1977; Douple & Richmond,
1978). Another platinum(IJ) complex, cis-
dichloro - bis(cyclopentylamine)platinum-
(II) potentiates damage due to X-rays in
aerated Chinese hamster ovary (CHO) cells
(Szumiel & Nias, 1976) and the plat-
inum(TV) complex cis-dichloro-bis(isopro-
pylamine)trans-dihydroxy platinum(JV)
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(CHIP), exhibits potentiation of X-ray
damage under hypoxic conditions
(Laverick & Nias, 1981). Nitroheterocycles
have also been widely studied as hypoxic
cell radiosensitizers on account ofthe high
electron affinity ofthe nitro group (Adams
et al., 1978; Willson, 1977). Thus, metro-
nidazole or Flagyl (1-(2-hydroxyethyl)-2-
methyl-5-nitroimidazole) (Fig. lb) has
undergone clinical trials (Urtasun et al.,
1978). Metronidazole is also preferentially
cytotoxic to hypoxic cells and hence is
widely used in the treatment of anaerobic
bacterial infections (Edwards et al., 1973).
Since the nitrogen at the 3-position of
metronidazole bears a lone pair of elec-
trons, it was decided to attempt the
synthesis of a complex ofthe type, Pt(Tl)-
(metronidazole)2CI2 (Fig. lc), preferably
with the chloride ligands in the cis
configuration. It was hoped that, as the
complex was neutral, it would readily pass
through cell membranes. As in the case of
Neoplatin, it has 2 potentially reactive cis702 J. R. BALES, P. J. SADLER, J. COULSON, M. LAVERICK AND A. H. W. NIAS
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FiG. 1. (a) Ci8-dichloro-diammine platinum(II); (b) 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole;
(c) cis-dichloro-bis( 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole-N3 )platinum(II).
chloride ligands which might enable it
specifically to attack guanine-cytosine rich
regions of DNA and bring both electron
affinic centres (platinum and NO2) near to
DNA, the target of radiation damage.
However, it was predicted that, unlike
Neoplatin, the new complex would not be
an anti-tumour agent in its own right,
since the nitrogens coordinated to plat-
inum do not bear hydrogen atoms. Indeed,
cis - dichloro - bis(imidazolo)platinum(II)
and substituted imidazole complexes
(without NO2 groups) have been reported
to exhibit only marginal cytostatic activ-
ity (Van Kralingen et al., 1979).
We describe the successful synthesis and
characterization of cis-platinum(metro-
nidazole)2C12 (FLAP) and its radiosensi-
tizing property when given as a pretreat-
ment to hypoxic cells in culture. The
enhancement ratio observed (2.4) was far
greater than could have been predicted
from results obtained from either metro-
nidazole alone or other platinum com-
plexes tested previously in the same
system. A brief report of this work has
already appeared (Laverick et al., 1982).
MATERIALS AND METHODS
Preparation and characterization of
FLAP.-Full chemical details will be pub-
lished elsewhere; a summary is given here.
Cis-platinum(metronidazole)2CI2 was pre-
pared, in high yield, by reacting K2PtCl4 with
2 molar-equivalents of metronidazole in
water. It can be recrystallized from acetone-
water, although it has a high level of purity
after the initial preparation. The purity was
confirmed by elemental analysis (C, H, N, Cl,
and Pt) and proton nuclear magnetic reson-
ance spectroscopy. Spin-spin coupling be-
tween the metronidazole C4-H and C2-methyl
hydrogen atoms and 195Pt, confirmed that
platinum was coordinated at the N3 nitrogen.
The complex is a stable yellow solid (m.p.
180-182°C), sparingly soluble in water (ca.
80 ,uM) but more soluble in acetone, dimethyl-
formamide, methoxyethanol and various
glycols. The polarographic halfwave potential
(El) recorded in phosphate buffer at pH 7 vs
an Ag/AgCl reference, was -0 27 V. This can
be compared with a value of - 0 47 V for
metronidazole alone under similar conditions.
The cis configuration of the complex was
confirmed by X-ray crystallography (Bales et
al. unpublished). The 2 chlorine and 2
nitrogen atoms form a square-plane around
platinum, the planes of the metronidazole
rings being approximately perpendicular to
this plane, tilted slightly with respect to each
other.
Cell culture.-CHO cells were grown in
monolayer culture in HEPES-buffered Mini-
mal Essential Medium (MEM) supplemented
with 15% calf serum, non-essential amino
acids and L-glutamine. Other methods of cell
culture together with the determination of
cell survival by their colony forming ability
after 5 days growth at 37°C have been
described previously (Szumiel & Nias, 1976;
Nias et al., 1979). Hypoxia was produced in
cells by the method ofNias et al. (1973).
Drug treatment.-FLAP was dissolved at a
concentration of 10 mg ml-1 in propylene
glycol with warming and diluted with MEM.
Metronidazole was dissolved in physiological
saline at a concentration of 25 mm. Stock
solutions ofCHIP and Neoplatin (supplied by
Johnson Matthey Ltd) were prepared at
1 mg ml-1 and 200 ,ug ml-1 respectively, in
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physiological saline. All solutions were kept in
the dark and freshly prepared before each
experiment. In all experiments the cells were
exposed to the drugs for 1 h at 37°C under
aerated conditions. The medium containing
the drug was then removed and replaced by
fresh medium. This was followed 1 h later by
X-irradiation in air or in hypoxia.
Irradiation.-X-rays of 250 kV were pro-
duced from a Maximar unit (HVL=0-83 mm
Cu) and the dose rate was 1-75 Gy min-1.
Dose-response curves.-The data points are
shown as mean survival (from at least 2
experiments per point) + the s.e. ofthe mean.
The exponential slope ofeach curve was fitted
to the data points by linear regression. This
exponential slope is used to describe the mean
lethal dose (Do) of drug or X-ray. Do is the
dose required to reduce the surviving fraction
by a factor of l/e (0 37) along the exponential
portion of the curve.
RESULTS AND DISCUSSION
The toxicity of FLAP was tested in
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terms of the clonogenic survival of CHO
cells and compared with CHIP and
Neoplatin in the same system (Fig. 2). The
dose-response curveconstructed for FLAP
is typical of other platinum coordination
complexes, having a "shoulder" region
followed by an exponential dose-response
to cell killing at the higher doses. In terms
of molarity FLAP (Do= 90 ,uM) is far less
toxic toCHO cellsthan CHIP (Do= 10 ,uM),
which is itself less toxic than Neoplatin
(Do= 3 EM). In our system metronidazole
is completely non-toxic up to a concentra-
tion of5 mM.
The toxicity of Neoplatin toward
tumour cells is thought to be related to its
ability to cause irreparable lesions on
DNA, probably via inter- or intra-strand
cross-links between guanine or cytosine
bases (Zwelling & Kohn, 1980). The
reactive cis chloride "leaving groups" are
thought to be involved in this cross-
linking, being replaced by the nitrogen
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FiG. 2. Dose-response curves for CHO cells treated for 1 h at 37°C with
Neoplatin (0), CHIP (x) and FLAP (9).
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FIG. 3.-Dose-response curves for CHO cells
treated with: X-rays alone in air (A, Do=
1-2 Gy), X-rays alone under hypoxia (@,
Do=3-4 Gy). X-rays in air 1 h after treat-
ment with 100 pM FLAP (LO, Do= 1-2 Gy),
X-rays under hypoxia 1 h after treatment
with 50 m FLAP (A, Do= 1-4 Gy), 500
lM FLAGYL (0, Do=2-3 Gy) or 70 joM
CHIP (x, Do=2-3 Gy). (Mean values of
at least 3 experiments/treatment.)
atoms ofguanine and cytosine. FLAP also
has reactive cis chloride ligands and would
be expected to react readily with guanine
and DNA.
One important difference may be that
FLAP, unlike Neoplatin and its analogues
(which are anti-tumourigenic) does not
have a hydrogen bound to the coordina-
ting nitrogen. The role played by this
hydrogen is still not fully understood. It
may play a critical part in platinum
complex/DNA hydrogen bonding. Mem-
brane transport may also play a role in the
differential toxicities observed. Platinum
uptake studies should clarify this point.
FLAP is more lipophilic than either
Neoplatin or CHIP.
The capacity of FLAP to potentiate X-
irradiation damage was compared with
metronidazole and CHIP using a 1-h delay
between drug and irradiation treatments
(Fig. 3). CHO cells were treated for 1 h at
37°C with non-toxic doses of either FLAP
(50 ,uM) or metronidazole (500 ptM) and
their effect was compared with a similar
pretreatment regime using 70 [M CHIP.
Enhancement of the radiation response
of hypoxic cells due to drug pretreatment
ofthe cells is shown in Fig. 3 by a decrease
in the final slope (Do) of the combined
modality dose response curves. This effect
is measured as an enhancement ratio (ER).
Because the extrapolation numbers (n) are
not significantly different, this enhance-
ment ratio is a true dose-modifying factor,
and sensitization is observed even at low
X-ray doses on the "shoulder" of the
combined modality curves.
The ER observed after pretreating cells
with 500 ,uM metronidazole was 1-5. How-
ever, even with a 10 x lower concentration
of FLAP (50 ,uM), a far greater potentia-
tion of X-ray cell killing was achieved,
with an ER of 2-4. This result can also be
compared with that obtained after the
slightly higher dose, 70 [kM, of the plat-
inum(IV) complex, CHIP. Pretreatment
with CHIP gave an ER of 1-5. At this high
dose, CHIP is toxic to CHO cells and the
combined modality curve has been nor-
malized with respect to CHIP toxicity.
Finally, we examined the combined effect
of FLAP pretreatment and X-irradiation
of CHO cells in air using a dose of 100 luM
FLAP. No enhancement of the radiation
response ofaerated cells was observed (i.e.
ER =10) withthis higher concentration of
FLAP. The OER of these cells is 2-8.
Further experiments would be required
to determine how metronidazole transport
into cells is affected by being part of a
platinum complex. The high level of
potentiation to X-ray cell killing may
arise, not only from DNA targeting via the
cis dichloride system, but also from the
synergism ofthe 2 types ofelectron affinic
centres in the FLAP molecule (Pt(II) and
NO2 groups). However it is evident from
the change in halfwave potential (El) that
the nitro group is perturbed when metro-
nidazole is bound to platinum; and thus
the properties ofbound metronidazole will
differ from those of free metronidazole.
In conclusion FLAP has been shown toHYPOXIC CELL SENSITIZATION BY FLAP 705
be veryeffective radiosensitizer ofhypoxic
cells in vitro at a non-toxic dose. Its effect,
producing an ER of2-4, is far greater than
could have been predicted from results
obained for metronidazole or other plat-
inum complexes tested so far in this
system. Also, at the higher dose used, no
corresponding sensitization ofaerated cells
was observed. Work is now in progress to
test the effectiveness of this complex as a
radiosensitizer in vivo.
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